Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
Open Access
- 1 April 2021
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (4), 1182-1187
- https://doi.org/10.3324/haematol.2020.253450
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyThe Lancet, 2019
- Insights into the management of older patients with multiple myeloma.2019
- The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple MyelomaClinical Cancer Research, 2019
- Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study designFuture Oncology, 2018
- CD38 antibodies in multiple myeloma: back to the futureBlood, 2018
- Multiple myeloma in the very elderly patient: challenges and solutionsClinical Interventions in Aging, 2015
- SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomideLeukemia, 2015
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic MalignanciesClinical Cancer Research, 2014
- Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trialsPublished by Ferrata Storti Foundation (Haematologica) ,2013
- Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent eraEuropean Journal of Haematology, 2012